416 related articles for article (PubMed ID: 37804358)
1. Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.
Ritu ; Chandra P; Das A
Clin Exp Med; 2023 Dec; 23(8):4297-4322. PubMed ID: 37804358
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
4. mRNA vaccine in gastrointestinal tumors: Immunomodulatory effects and immunotherapy.
Zhang A; Ji Q; Sheng X; Wu H
Biomed Pharmacother; 2023 Oct; 166():115361. PubMed ID: 37660645
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
Knaus HA; Kanakry CG; Luznik L; Gojo I
Curr Drug Targets; 2017; 18(3):315-331. PubMed ID: 25981611
[TBL] [Abstract][Full Text] [Related]
6. Role of cell surface proteoglycans in cancer immunotherapy.
Espinoza-Sánchez NA; Götte M
Semin Cancer Biol; 2020 May; 62():48-67. PubMed ID: 31336150
[TBL] [Abstract][Full Text] [Related]
7. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
8. Recent Advancements on Immunomodulatory Mechanisms of Resveratrol in Tumor Microenvironment.
Chhabra G; Singh CK; Amiri D; Akula N; Ahmad N
Molecules; 2021 Mar; 26(5):. PubMed ID: 33802331
[TBL] [Abstract][Full Text] [Related]
9. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets.
Ray SK; Mukherjee S
Curr Drug Targets; 2022; 23(5):471-485. PubMed ID: 35021970
[TBL] [Abstract][Full Text] [Related]
10. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
Varricchi G; Loffredo S; Marone G; Modestino L; Fallahi P; Ferrari SM; de Paulis A; Antonelli A; Galdiero MR
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412566
[TBL] [Abstract][Full Text] [Related]
11. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy.
Osipov A; Murphy A; Zheng L
Adv Cancer Res; 2019; 143():63-144. PubMed ID: 31202363
[TBL] [Abstract][Full Text] [Related]
12. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
13. Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy.
Kiaie SH; Salehi-Shadkami H; Sanaei MJ; Azizi M; Shokrollahi Barough M; Nasr MS; Sheibani M
J Nanobiotechnology; 2023 Sep; 21(1):339. PubMed ID: 37735656
[TBL] [Abstract][Full Text] [Related]
14. Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer.
Gupta M; Chandan K; Sarwat M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):214-232. PubMed ID: 35772610
[TBL] [Abstract][Full Text] [Related]
15. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies.
Muhammad S; Fan T; Hai Y; Gao Y; He J
Mol Cancer; 2023 Jul; 22(1):121. PubMed ID: 37516849
[TBL] [Abstract][Full Text] [Related]
16. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Borcherding N; Kolb R; Gullicksrud J; Vikas P; Zhu Y; Zhang W
J Mol Biol; 2018 Jul; 430(14):2014-2029. PubMed ID: 29800567
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets.
Zhong Z; Vong CT; Chen F; Tan H; Zhang C; Wang N; Cui L; Wang Y; Feng Y
Med Res Rev; 2022 May; 42(3):1246-1279. PubMed ID: 35028953
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy: the art of targeting the tumor immune microenvironment.
da Silva JL; Dos Santos ALS; Nunes NCC; de Moraes Lino da Silva F; Ferreira CGM; de Melo AC
Cancer Chemother Pharmacol; 2019 Aug; 84(2):227-240. PubMed ID: 31240384
[TBL] [Abstract][Full Text] [Related]
20. Dual-Targeting Nanoliposome Improves Proinflammatory Immunomodulation of the Tumor Microenvironment.
Gu Z; da Silva CG; Ma S; Liu Q; Schomann T; Ossendorp F; Cruz LJ
Adv Healthc Mater; 2023 Dec; 12(31):e2302046. PubMed ID: 37605325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
